Fortune: Why the Drug Price Scandal won’t be Enough to Keep Down Prices

Fortune: Why the Drug Price Scandal won’t be Enough to Keep Down Prices

A little-known drug called Daraprim captured national attention in September when Turing Pharmaceuticals boosted the price of the lifesaving toxoplasmosis treatment by over 5,000%. Overnight, Turing CEO Martin Shkreli became the poster child for bad business in the pharmaceutical industry, skewered for what was seen as price gouging, leaving very ill patients without treatment.

Read more

Topics: News

Posted by

Truveris Team